SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Benedetti Andrea)
 

Sökning: WFRF:(Benedetti Andrea) > Ibrutinib combined ...

  • Dreyling, MartinUniversity Hospital Munich (författare)

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE) : a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • 2024
  • 14 s.

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:9b9b00ca-3492-4083-854f-8af5d1f729bb
  • https://lup.lub.lu.se/record/9b9b00ca-3492-4083-854f-8af5d1f729bbURI
  • https://doi.org/10.1016/S0140-6736(24)00184-3DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Background: Adding ibrutinib to standard immunochemotherapy might improve outcomes and challenge autologous stem-cell transplantation (ASCT) in younger (aged 65 years or younger) mantle cell lymphoma patients. This trial aimed to investigate whether the addition of ibrutinib results in a superior clinical outcome compared with the pre-trial immunochemotherapy standard with ASCT or an ibrutinib-containing treatment without ASCT. We also investigated whether standard treatment with ASCT is superior to a treatment adding ibrutinib but without ASCT. Methods: The open-label, randomised, three-arm, parallel-group, superiority TRIANGLE trial was performed in 165 secondary or tertiary clinical centres in 13 European countries and Israel. Patients with previously untreated, stage II–IV mantle cell lymphoma, aged 18–65 years and suitable for ASCT were randomly assigned 1:1:1 to control group A or experimental groups A+I or I, stratified by study group and mantle cell lymphoma international prognostic index risk groups. Treatment in group A consisted of six alternating cycles of R-CHOP (intravenous rituximab 375 mg/m2 on day 0 or 1, intravenous cyclophosphamide 750 mg/m2 on day 1, intravenous doxorubicin 50 mg/m2 on day 1, intravenous vincristine 1·4 mg/m2 on day 1, and oral prednisone 100 mg on days 1–5) and R-DHAP (or R-DHAOx, intravenous rituximab 375 mg/m2 on day 0 or 1, intravenous or oral dexamethasone 40 mg on days 1–4, intravenous cytarabine 2 × 2 g/m2 for 3 h every 12 h on day 2, and intravenous cisplatin 100 mg/m2 over 24 h on day 1 or alternatively intravenous oxaliplatin 130 mg/m2 on day 1) followed by ASCT. In group A+I, ibrutinib (560 mg orally each day) was added on days 1–19 of R-CHOP cycles and as fixed-duration maintenance (560 mg orally each day for 2 years) after ASCT. In group I, ibrutinib was given the same way as in group A+I, but ASCT was omitted. Three pairwise one-sided log-rank tests for the primary outcome of failure-free survival were statistically monitored. The primary analysis was done by intention-to-treat. Adverse events were evaluated by treatment period among patients who started the respective treatment. This ongoing trial is registered with ClinicalTrials.gov, NCT02858258. Findings: Between July 29, 2016 and Dec 28, 2020, 870 patients (662 men, 208 women) were randomly assigned to group A (n=288), group A+I (n=292), and group I (n=290). After 31 months median follow-up, group A+I was superior to group A with 3-year failure-free survival of 88% (95% CI 84–92) versus 72% (67–79; hazard ratio 0·52 [one-sided 98·3% CI 0–0·86]; one-sided p=0·0008). Superiority of group A over group I was not shown with 3-year failure-free survival 72% (67–79) versus 86% (82–91; hazard ratio 1·77 [one-sided 98·3% CI 0–3·76]; one-sided p=0·9979). The comparison of group A+I versus group I is ongoing. There were no relevant differences in grade 3–5 adverse events during induction or ASCT between patients treated with R-CHOP/R-DHAP or ibrutinib combined with R-CHOP/R-DHAP. During maintenance or follow-up, substantially more grade 3–5 haematological adverse events and infections were reported after ASCT plus ibrutinib (group A+I; haematological: 114 [50%] of 231 patients; infections: 58 [25%] of 231; fatal infections: two [1%] of 231) compared with ibrutinib only (group I; haematological: 74 [28%] of 269; infections: 52 [19%] of 269; fatal infections: two [1%] of 269) or after ASCT (group A; haematological: 51 [21%] of 238; infections: 32 [13%] of 238; fatal infections: three [1%] of 238). Interpretation: Adding ibrutinib to first-line treatment resulted in superior efficacy in younger mantle cell lymphoma patients with increased toxicity when given after ASCT. Adding ibrutinib during induction and as maintenance should be part of first-line treatment of younger mantle cell lymphoma patients. Whether ASCT adds to an ibrutinib-containing regimen is not yet determined. Funding: Janssen and Leukemia & Lymphoma Society.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Doorduijn, JeanetteErasmus University Medical Center (författare)
  • Giné, EvaHospital Clínic of Barcelona (författare)
  • Jerkeman, MatsLund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Onkologi övergripande,Institutionen för kliniska vetenskaper, Lund,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lymphoma - Clinical Research,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Oncology corporate,Department of Clinical Sciences, Lund(Swepub:lu)onk-mje (författare)
  • Walewski, JanThe Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (författare)
  • Hutchings, MartinCopenhagen University Hospital (författare)
  • Mey, UlrichCantonal Hospital Graubunden (författare)
  • Riise, JonOslo university hospital (författare)
  • Trneny, MarekCharles University in Prague (författare)
  • Vergote, VibekeUniversity Hospitals Leuven (författare)
  • Shpilberg, OferAriel University,Assuta Medical Center (författare)
  • Gomes da Silva, MariaPortuguese Institute Of Oncology (författare)
  • Leppä, SirpaUniversity of Helsinki (författare)
  • Jiang, LinmiaoLudwig-Maximilian University of Munich (författare)
  • Stilgenbauer, StephanUniversity Hospital of Ulm (författare)
  • Kerkhoff, AndreaUniversity Hospital Münster (författare)
  • Jachimowicz, Ron D.University Hospital of Cologne (författare)
  • Celli, Melania (författare)
  • Hess, GeorgUniversitätsmedizin Mainz (författare)
  • Arcaini, LucaUniversity of Pavia,Policlinico San Matteo Pavia Fondazione (författare)
  • Visco, CarloVerona University Medical School,Ospedale San Bortolo (författare)
  • van Meerten, TomUniversity Medical Center Groningen (författare)
  • Wirths, StefanUniversity Hospital of Tubingen (författare)
  • Zinzani, Pier LuigiSt. Orsola-Malpighi University Hospital,University of Bologna (författare)
  • Novak, UrbanBern University Hospital (författare)
  • Herhaus, PeterTechnical University of Munich (författare)
  • Benedetti, FabioUniversity of Verona (författare)
  • Sonnevi, KristinaKarolinska Institute (författare)
  • Hanoun, ChristineUniversity Hospital Essen (författare)
  • Hänel, Matthias (författare)
  • Dierlamm, Judith (författare)
  • Pott, ChristianeUniversity Medical Center Schleswig-Holstein (författare)
  • Klapper, WolframUniversity Medical Center Schleswig-Holstein (författare)
  • Gözel, DöndüUniversity Hospital Munich (författare)
  • Schmidt, ChristianUniversity Hospital Munich (författare)
  • Unterhalt, MichaelUniversity Hospital Munich (författare)
  • Ladetto, MarcoUniversity of Eastern Piedmont (författare)
  • Hoster, EvaLudwig-Maximilian University of Munich (författare)
  • University Hospital MunichErasmus University Medical Center (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:The Lancet403:10441, s. 2293-23060140-6736

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy